HomeCompareGBRRF vs ABBV

GBRRF vs ABBV: Dividend Comparison 2026

GBRRF yields 2173.91% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBRRF wins by $21654764992.45M in total portfolio value
10 years
GBRRF
GBRRF
● Live price
2173.91%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21654764992.55M
Annual income
$19,857,848,853,590,590.00
Full GBRRF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GBRRF vs ABBV

📍 GBRRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGBRRFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GBRRF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GBRRF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GBRRF
Annual income on $10K today (after 15% tax)
$184,782.61/yr
After 10yr DRIP, annual income (after tax)
$16,879,171,525,552,002.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, GBRRF beats the other by $16,879,171,525,530,946.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GBRRF + ABBV for your $10,000?

GBRRF: 50%ABBV: 50%
100% ABBV50/50100% GBRRF
Portfolio after 10yr
$10827382496.33M
Annual income
$9,928,924,426,807,682.00/yr
Blended yield
91.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GBRRF
No analyst data
Altman Z
-857.0
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GBRRF buys
0
ABBV buys
0
No recent congressional trades found for GBRRF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGBRRFABBV
Forward yield2173.91%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$21654764992.55M$102.3K
Annual income after 10y$19,857,848,853,590,590.00$24,771.77
Total dividends collected$21528016497.42M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GBRRF vs ABBV ($10,000, DRIP)

YearGBRRF PortfolioGBRRF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$228,091$217,391.30$11,550$430.00+$216.5KGBRRF
2$4,878,176$4,634,118.33$13,472$627.96+$4.86MGBRRF
3$97,845,472$92,625,823.19$15,906$926.08+$97.83MGBRRF
4$1,841,021,843$1,736,327,188.73$19,071$1,382.55+$1841.00MGBRRF
5$32,502,648,796$30,532,755,424.15$23,302$2,095.81+$32502.63MGBRRF
6$538,559,125,266$503,781,291,054.08$29,150$3,237.93+$538559.10MGBRRF
7$8,377,664,463,744$7,801,406,199,709.04$37,536$5,121.41+$8377664.43MGBRRF
8$122,381,239,723,864$113,417,138,747,658.05$50,079$8,338.38+$122381239.67MGBRRF
9$1,679,360,877,531,610$1,548,412,951,027,075.00$69,753$14,065.80+$1679360877.46MGBRRF
10$21,654,764,992,549,412$19,857,848,853,590,590.00$102,337$24,771.77+$21654764992.45MGBRRF

GBRRF vs ABBV: Complete Analysis 2026

GBRRFStock

Gabriel Resources Ltd. engages in the exploration, evaluation, and development of precious metal mining properties in Romania. The company primarily explores for gold, silver, and copper deposits. It primarily holds interest in the Bucium exploration concession covering an area of 2,325 hectares located in Western Transylvania. The company was formerly known as Starx Resource Corp. and changed its name to Gabriel Resources Ltd. in April 1997. Gabriel Resources Ltd. was incorporated in 1986 and is based in Whitehorse, Canada.

Full GBRRF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GBRRF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GBRRF vs SCHDGBRRF vs JEPIGBRRF vs OGBRRF vs KOGBRRF vs MAINGBRRF vs JNJGBRRF vs MRKGBRRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.